ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting

    Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose

    Juliana Valim1, Verônica Lima2, Fernanda Guimarães3, Fernanda Chaer4 and Branca Souza5, 1Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, 2Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil, 3Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, 4Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, 5Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil

    Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…
  • Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting

    Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual

    Hironari Hanaoka1, Hidehiro Yamada2, Tomofumi Kiyokawa3, Harunobu Iida1, Takeshi Suzuki1, Yoshioki Yamasaki4, Seido Ooka5, Hiroko Nagafuchi3, Takahiro Okazaki3, Daisuke Ichikawa6, Sayuri Shirai6, Yugo Shibagaki7, Junki Koike8 and Shoichi Ozaki3, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, 3Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 4Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, 5Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 7Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, 8Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
  • Abstract Number: 2827 • 2016 ACR/ARHP Annual Meeting

    Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death

    Cristina Arriens1, Sixia Chen2, David Karp3, Ramesh Saxena4, Kamalanathan Sambandam4, Eliza Chakravarty1, Judith A. James5 and Joan T. Merrill6, 1Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 4Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, 5Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose:  Approximately half of SLE patients develop lupus nephritis (LN), a major cause of morbidity and early mortality. It is known that prolonged renal inflammation…
  • Abstract Number: 2829 • 2016 ACR/ARHP Annual Meeting

    Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis

    Eleana Ntatsaki1, Alba Velo Garcia2, Alan D. Salama3 and David A. Isenberg4, 1Centre for Rheumatology, University College London, London, United Kingdom, 2Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, 3Centre for Nephrology, University College London, London, United Kingdom, 4Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential…
  • Abstract Number: 2842 • 2016 ACR/ARHP Annual Meeting

    Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis

    William Fung1, Jiandong Su2 and Zahi Touma3, 1Medicine, University of Toronto, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose:   Lupus nephritis (LN) manifests with proteinuria and/or active urine sediment. Renal composite indices include proteinuria, urinary active sediment (RBCs, casts) and serum creatinine.…
  • Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting

    Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis

    Ruth J. Pepper1, Venkat Reddy2, Scott Henderson3 and Maria J. Leandro4, 1UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom, 2Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 3UCL Centre for Nephrology, University College London, London, United Kingdom, 4Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…
  • Abstract Number: 2852 • 2016 ACR/ARHP Annual Meeting

    Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare

    Aymeric Couturier1, Vincent Molinie2, Charles Cartou3, Serge ARFI4, Violaine Emal-Aglae5, Katlyne Polomat6, Florence MOINET6, Georges JEAN BAPTISTE7 and Christophe Deligny8, 1nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, 2Pathology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, 3nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, 4University Hospital, CHU Fort de France, Fort de France, Martinique, 5Nephrology, Centre Hospitalier de Mangot-Vulcin, Le Lamentin, Martinique, 6Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, 7RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, 8Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique

    Background/Purpose:  In African-descent patients, lupus nephritis (LN) lead to a worse outcome than in Caucasians. Long term data are rare in countries where black populations…
  • Abstract Number: 749 • 2016 ACR/ARHP Annual Meeting

    Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis

    Richard Furie1, Ana Malvar2, Sandra V. Navarra3, Karen Smirnakis4, Jessica Kong4, Nathalie Franchimont4 and Fei Shih4, 1Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, 2Nephrology Division, Hospital Fernandez, Buenos Aires, Argentina, 3Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 4Biogen, Cambridge, MA

    Background/Purpose:  The addition of an anti-TWEAK monoclonal antibody to SOC LN therapy did not improve 52-week RR rates in proliferative LN despite observed pharmacodynamic effects.…
  • Abstract Number: 2855 • 2016 ACR/ARHP Annual Meeting

    The Long-Term Clinical Outcomes of Lupus Nephritis

    Julie Davidson1, Qinggong Fu2, Beulah Ji3, Sapna Rao4, David Roth5, Laurence S Magder6 and Michelle Petri7, 1Worldwide Epidemiology, GlaxoSmithKline R&D, Uxbridge, United Kingdom, 2Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA, 3Clinical Development, GlaxoSmithKline R&D, Uxbridge, United Kingdom, 4Real World Evidence, GlaxoSmithKline R&D, Research Triangle Park, NC, 5GSK, Philadelphia, PA, 6Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, 7Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Clinical trials in lupus nephritis have often been designed to demonstrate renal response (or remission) following therapy based on categorical remission endpoints (often no…
  • Abstract Number: 1180 • 2016 ACR/ARHP Annual Meeting

    Class V Lupus Nephritis Results in Significant Numbers of End Stage Renal Disease and Death in a Population-Based Registry

    Jennifer Brandt1, Cristina Drenkard2, Jason Cobb3, Gaobin Bao4 and S. Sam Lim4, 1Department of Rheumatology, Emory University School of Medicine, Atlanta, GA, 2Emory University School of Medicine, Atlanta, GA, 3Department of Nephrology, Emory University School of Medicine, Atlanta, GA, 4Medicine, Emory University School of Medicine, Atlanta, GA

    Background/Purpose: Although the diagnosis of pure class V lupus nephritis (LN) is generally thought to portend a favorable prognosis, outcomes on a population-level are not…
  • Abstract Number: 3104 • 2016 ACR/ARHP Annual Meeting

    Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis

    Michelle Lopes1, Luciana Seguro1, Maite Castro2, Danielle Daffre3, Eduardo Ferreira Borba2 and Eloisa Bonfa4, 1Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 3São Paulo University, São Paulo, Brazil, 4Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

    Background/Purpose: Treat to target strategies are becoming the best approach for several rheumatic disorders. Recently retrospective analyses of two important lupus trials have reported that…
  • Abstract Number: 1394 • 2016 ACR/ARHP Annual Meeting

    A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis

    Jennifer C. Cooper1, B. Anne Eberhard2, Marilynn Punaro3, Stacy P. Ardoin4, Hermine I. Brunner5, Joyce Hsu6, Linda Wagner-Weiner7, Kelly Rouster-Stevens8, Laura E. Schanberg9, Marisa Klein-Gitelman10, Emily von Scheven11 and CARRA Registry Investigators, 1Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Cohen Children's Medical Center of New York, New Hyde Park, NY, 3Texas Scottish Rite Hospital for Children, Dallas, TX, 4Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, 5Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Pediatric Rheumatology, Stanford University, Palo Alto, CA, 7Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 8Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, 9Pediatrics, Duke Medical Center, Durham, NC, 10Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, 11Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA

    Background/Purpose:   Childhood-onset systemic lupus erythematous (cSLE) patients are at higher risk for renal disease than those with adult-onset disease. Mycophenolate mofetil (MMF) and intravenous…
  • Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting

    Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis

    Jeffrey Hampton1, Nicholas A. Young2, Sudha Agarwal3, Saba Aqel3, Kendra Jones3, Lai-Chu Wu2,4, Nicole Powell5, John Sheridan5, Michael Bruss3 and Wael N. Jarjour2, 1Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, 2Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 3Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 4Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, 5Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose:  Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage.  Our group has previously shown that moderate daily exercise reduces systemic inflammation…
  • Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting

    Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

    Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea

    Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
  • Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting

    Real Life Implementation of Lupus Nephritis Randomized Controlled Trials

    Angela Pakozdi1, Ravindra Rajakariar2, Muhammad Magdi Yaqoob2 and Dev Pyne1, 1Rheumatology, Barts Health NHS Trust, London, United Kingdom, 2Renal Medicine, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology